Wells Fargo’s Elevation Oncology ELEV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-444
| Closed | -$163 | – | 7165 |
|
|
2025
Q2 | $163 | Sell |
444
-29,235
| -99% | -$9.76K | ﹤0.01% | 6451 |
|
|
2025
Q1 | $7.69K | Buy |
29,679
+654
| +2% | +$373 | ﹤0.01% | 5943 |
|
|
2024
Q4 | $16.3K | Buy |
29,025
+9,859
| +51% | +$5.82K | ﹤0.01% | 5811 |
|
|
2024
Q3 | $11.5K | Buy |
19,166
+20
| +0.1% | +$30 | ﹤0.01% | 5763 |
|
|
2024
Q2 | $51.7K | Buy |
19,146
+18,901
| +7,715% | +$71.2K | ﹤0.01% | 5279 |
|
|
2024
Q1 | $1.26K | Buy |
245
+4
| +2% | +$13 | ﹤0.01% | 6101 |
|
|
2023
Q4 | $129 | Buy |
241
+12
| +5% | +$6 | ﹤0.01% | 6707 |
|
|
2023
Q3 | $152 | Buy |
229
+131
| +134% | +$132 | ﹤0.01% | 6647 |
|
|
2023
Q2 | $149 | Buy |
98
+6
| +7% | +$16 | ﹤0.01% | 6779 |
|
|
2023
Q1 | $175 | Buy |
92
+2
| +2% | +$3 | ﹤0.01% | 6807 |
|
|
2022
Q4 | $86 | Buy |
90
+2
| +2% | +$2 | ﹤0.01% | 6833 |
|
|
2022
Q3 | $0 | Buy |
88
+46
| +110% | +$58 | ﹤0.01% | 6810 |
|
|
2022
Q2 | $0 | Buy |
42
+3
| +8% | +$8 | ﹤0.01% | 6958 |
|
|
2022
Q1 | $0 | Buy |
39
+1
| +3% | +$4 | ﹤0.01% | 7224 |
|
|
2021
Q4 | $0 | Hold |
38
| – | – | ﹤0.01% | 7343 |
|
|
2021
Q3 | $0 | Buy |
+38
| New | +$411 | ﹤0.01% | 7071 |
|
Other funds holding ELEV
Wells Fargo's ELEV Position: Q3 2025 in Review
Wells Fargo sold out of Elevation Oncology (ELEV) in Q3 2025, closing a stake of 444 shares — an estimated $163 sold.
Wells Fargo first reported a position in ELEV in Q3 2021 and held it in 16 quarters. The position peaked at $51.7K in Q2 2024. 1 fund tracked by Wall St. Rank holds ELEV as of Q3 2025.
- Wells Fargo reported no remaining Elevation Oncology position as of Q3 2025 after selling out during the quarter.
- Wells Fargo sold 444 Elevation Oncology shares in Q3 2025, an estimated $163.
- Wells Fargo first reported a position in Elevation Oncology in Q3 2021 and held it in 16 quarters.
- Wells Fargo's Elevation Oncology position peaked at $51.7K in Q2 2024.
- 1 fund tracked by Wall St. Rank held Elevation Oncology as of Q3 2025.
Based on Wells Fargo's 13F filing for Q3 2025, filed 13 Nov 2025.